赛马鲁肽
医学
利西塞纳泰德
杜拉鲁肽
艾塞那肽
利拉鲁肽
耐受性
2型糖尿病
肠促胰岛素
胰高血糖素样肽1受体
恩帕吉菲
药理学
临床试验
不利影响
糖尿病
内科学
内分泌学
受体
兴奋剂
作者
Anoop Mohamed Iqbal,Nasvin Imamudeen,Amjad Basheer,Sukrita Menon,Gisha Mohan,Tesil Nedumkallel Sani,Nisha Nigil Haroon
出处
期刊:Current Drug Safety
[Bentham Science]
日期:2020-12-09
卷期号:16 (2): 197-206
被引量:11
标识
DOI:10.2174/1574886315999201208212356
摘要
Abstract:: Glucagon-like peptide- 1 receptor analogs (GLP-1RAs) are incretin mimetics with potent glucose-dependent insulinotropic action that translates to glycemic control in people with type- -2 diabetes mellitus (T2DM). These agents potentially have the ability to stimulate proliferation or prevent apoptosis of pancreatic β-cells, induce weight-loss and provide vascular benefits in patients with T2DM. Newer GLP-1RA, semaglutide has shown a robust reduction in HbA1c up to 1.5 - 1.8%. However, individual differences exist between the different GLP-1RAs, in terms of efficacy, pharmacokinetics, tolerability, and vascular protection. The potential of vascular protection offered by newer anti-diabetic agents has generated a lot of excitement in the field of diabetes, and to a large extent, is now driving treatment decisions. So far, six cardiovascular outcome trials of GLP-1 RAs have been published, analyzing lixisenatide (ELIXA), liraglutide (LEADER), semaglutide (SUSTAIN-6), long-acting exenatide (EXSCEL), dulaglutide (REWIND), and oral semaglutide (PIONEER 6) with a follow-up duration of 2-4 years. LEADER, REWIND and SUSTAIN-6 trials have demonstrated a reduction in rates of major adverse cardiovascular events with active GLP-1 RA treatment, but ELIXA, PIONEER 6 and EXSCEL, have been neutral. In this review, we discuss the available evidence from randomized controlled trials (RCTs) analyzing the cardiovascular effects of various GLP-1 RAs with the aim of comparing individual drugs. We have also summarized the general aspects of GLP-1RAs that can be applied in clinical practice.
科研通智能强力驱动
Strongly Powered by AbleSci AI